The Asia-Pacific (APAC) region has rapidly emerged as one of the most dynamic markets in global clinical development. Over the past decade, demand for innovative the...

As artificial intelligence (AI) gains prominence in drug development, regulatory agencies such as the US Food and Drug Administration (FDA) are creating and implemen...

The UK biotech sector is thriving and with significant investment flowing into research, the opportunities for growth and innovation are considerable. In 2024, UK bi...

 Ahead of ARVO 2025 next week where Emmes is poised to launch the first dedicated ophthalmology clinical trial technology platform, we spoke with Saqib Parkar, ...

“All organisations, even the most renowned and successful, sometimes make the right things too hard and the wrong things too easy.”1 Sutton and Rao address this prob...

Europe’s regulatory environment is shifting fast. In the clinical trials space, recent years have brought sweeping changes, shaped by initiatives like the General Da...

Rare diseases, also known as orphan diseases, affect an estimated 300 million people worldwide, yet each individual condition impacts a relatively small patient popu...

Committees (DMCs) has never been more critical in ensuring patient safety and trial integrity, especially as clinical trials become more complex and globalised. In r...

The discovery and integration of cancer biomarkers into oncology research has transformed how cancer is detected, diagnosed and treated. As precision medicine contin...

The need for a UK national screening programme to enable early detection of prostate cancer is now more important than ever, with one in six men receiving a prostate...